Atrium Therapeutics Inc. Common Stock (RNA)

About RNA

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyo…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Website

atriumtherapeutics.com

Fundamentals

1-day range

$12.85$13.72

Market cap

$207.15M

P/E (trailing)

—

P/E (forward)

-1.70

EPS (trailing)

$-5.82

Dividend yield

—

Beta

—

Avg. volume

194.2K

Forecasts

4 analyst ratings

Atrium Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• RNA

  Atrium Therapeutics Inc. Common Stock

  $13.64

  ▼ 2.43%
  Market cap $207.15MP/E —
  $11.13$16.77
• NERV

  Minerva Neurosciences Inc Common Stock

  $4.85

  ▼ 5.56%
  Market cap $206.85MP/E —
  $1.93$12.46
• GLSI

  Greenwich LifeSciences Inc. Common Stock

  $15.67

  ▼ 16.34%
  Market cap $209.02MP/E —
  $7.78$34.1
• MSLE

  Satellos Bioscience Inc. Common Stock

  $8.92

  ▼ 7.23%
  Market cap $209.77MP/E —
  $7.08$18.98
• NBP

  NovaBridge Biosciences American Depositary Shares

  $1.85

  ▼ 2.38%
  Market cap $196.15MP/E —
  $1.46$6.79
• SIGA

  SIGA Technologies Inc. Common Stock

  $3.07

  ▲ 0.33%
  Market cap $223.78MP/E —
  $2.83$9.45
• TNXP

  Tonix Pharmaceuticals Holding Corp. Common Stock

  $13.59

  ▲ 0.18%
  Market cap $185.71MP/E —
  $9.4$33.22

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• HC Wainwright & Co. Reiterates Buy on Atrium Therapeutics, Maintains $25 Price Target
  benzinga · 8/14/2026
• HC Wainwright & Co. Reiterates Buy on Atrium Therapeutics, Maintains $25 Price Target
  Benzinga · 8/14/2026
• Atrium Therapeutics Q2 EPS $(1.18) Misses $(1.01) Estimate, Sales $3.004M Beat $2.000M Estimate
  Benzinga · 8/13/2026
• Benzinga's Volume Movers
  Benzinga · 8/13/2026
• This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
  Benzinga · 8/6/2026
• HC Wainwright & Co. Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $25
  Benzinga · 8/6/2026

• Stephanie Kenney · April 20, 2026 · Grant

  60.0K
• Stephanie Kenney · April 20, 2026 · Grant

  30.0K
• Brendan R. Winslow · April 20, 2026 · Grant

  60.0K
• Brendan R. Winslow · April 20, 2026 · Grant

  30.0K
• Rocio Martin Hoyos · April 20, 2026 · Grant

  60.0K
• Rocio Martin Hoyos · April 20, 2026 · Grant

  30.0K
• Husam Younis · April 20, 2026 · Grant

  60.0K
• Husam Younis · April 20, 2026 · Grant

  30.0K
• Kathleen P. Gallagher · April 20, 2026 · Grant

  205.0K
• Kathleen P. Gallagher · April 20, 2026 · Grant

  102.5K
• Steven George Hughes · April 20, 2026 · Grant

  60.0K
• Steven George Hughes · April 20, 2026 · Grant

  30.0K

Institutional Ownership

March 31, 2026

Total shares held

15.61M

Total value held

$186.28M

Institutional holders

159